It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Not every neonate with congenital Zika virus (ZIKV) infection (CZI) is born with microcephaly. We compared inflammation mediators in CSF (cerebrospinal fluid obtained from lumbar puncture) between ZIKV-exposed neonates with/without microcephaly (cases) and controls. In Brazil, in the same laboratory, we identified 14 ZIKV-exposed neonates during the ZIKV epidemic (2015–2016), 7(50%) with and 7(50%) without microcephaly, without any other congenital infection, and 14 neonates (2017–2018) eligible to be controls and to match cases. 29 inflammation mediators were measured using Luminex immunoassay and multidimensional analyses were employed. Neonates with ZIKV-associated microcephaly presented substantially higher degree of inflammatory perturbation, associated with uncoupled inflammatory response and decreased correlations between concentrations of inflammatory biomarkers. The groups of microcephalic and non-microcephalic ZIKV-exposed neonates were distinguished from the control group (area under curve [AUC] = 1; P < 0.0001). Between controls and those non-microcephalic exposed to ZIKV, IL-1β, IL-3, IL-4, IL-7 and EOTAXIN were the top CSF markers. By comparing the microcephalic cases with controls, the top discriminant scores were for IL-1β, IL-3, EOTAXIN and IL-12p70. The degree of inflammatory imbalance may be associated with microcephaly in CZI and it may aid additional investigations in experimental pre-clinical models testing immune modulators in preventing extensive damage of the Central Nervous System.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Bahiana School of Medicine, Bahiana Foundation for Science Development, Salvador, Brazil (GRID:grid.414171.6) (ISNI:0000 0004 0398 2863)
2 José Silveira Foundation, Cerebrospinal Fluid Laboratory, Salvador, Brazil (GRID:grid.414171.6)
3 Bahiana School of Medicine, Bahiana Foundation for Science Development, Salvador, Brazil (GRID:grid.414171.6) (ISNI:0000 0004 0398 2863); Oswaldo Cruz Foundation, Gonçalo Moniz Institute, Salvador, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931); Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil (GRID:grid.418068.3)
4 Oswaldo Cruz Foundation, Gonçalo Moniz Institute, Salvador, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931); Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil (GRID:grid.418068.3); University Salvador (UNIFACS), Laureate Universities, Salvador, Brazil (GRID:grid.442056.1) (ISNI:0000 0001 0166 9177)
5 Oswaldo Cruz Foundation, Gonçalo Moniz Institute, Salvador, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931); Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil (GRID:grid.418068.3)
6 Bahiana School of Medicine, Bahiana Foundation for Science Development, Salvador, Brazil (GRID:grid.414171.6) (ISNI:0000 0004 0398 2863); Oswaldo Cruz Foundation, Gonçalo Moniz Institute, Salvador, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931); Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil (GRID:grid.418068.3); University Salvador (UNIFACS), Laureate Universities, Salvador, Brazil (GRID:grid.442056.1) (ISNI:0000 0001 0166 9177); Faculdade de Tecnologia e Ciências (Uni-FTC), School of Medicine, Salvador, Brazil (GRID:grid.467298.6) (ISNI:0000 0004 0471 7789); University of Cape Town, Wellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa (GRID:grid.7836.a) (ISNI:0000 0004 1937 1151); Vanderbilt University School of Medicine, Division of Infectious Diseases, Department of Medicine, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
7 Federal University of Bahia School of Medicine, Department of Pediatrics, Salvador, Brazil (GRID:grid.8399.b) (ISNI:0000 0004 0372 8259)